摘要目的 探讨二肽基肽酶(DPP-4)抑制剂利格列汀对糖尿病肾病预后的影响.方法 将确诊为临床糖尿病肾病的46例患者随机分为对照组20例和观察组26例,两组均采用皮下注射胰岛素+α糖苷酶抑制剂(阿卡波糖等)/PPAR-γ激动剂(罗格列酮等)治疗,分组后,对照组维持原治疗方案不变,观察组在原降糖方案基础上加用利格列汀100 mg/d,两组均治疗16周.观察两组血清肌酐(SCr)、尿素氮(BUN)、血清胱抑素C(CysC)、血清C-反应蛋白(C-RP)、白细胞介素-6(IL-6)及尿白蛋白排泄率(UAER)等预后指标的变化.结果 治疗后,利格列汀组患者血清CysC、CRP、IL-6、UAER等指标低于对照组,差异有统计学意义(P＜0.05).结论 利格列汀能够改善临床糖尿病肾病患者的肾脏损害程度.

abstractsObjective To investigate the prognostic of linagliptin (DPP-4) inhibitor on diabetic nephropathy in clinics.Methods Fourty-six patients diagnosed as diabetic nephropathy were randomly divided into control group (n =20) and observation group (n =26).All patients underwent subcutaneous insulin infusion + α-glycosidase inhibitors;after grouping,the control group maintained the original treatment plan,while the patients of observation group,on the basis of the original hypoglycemic scheme,were given linagliptin 100 mg per day.The two groups were treated for 16 weeks.Levels of serum creatinine (SCr),blood urea nitrogen (BUN),Cystatin-C (CysC),C-reactive protein (CRP),interleukin-6 (IL-6),urinary albumin excretion rate (UAER) were observed.Results Compared with control group,the level of CysC,CRP,IL-6 and UAER in observation group decreased more obviously,the differences between the two groups showed statistical significance (P ＜ 0.05).Conclusions Linagliptin can significantly improve renal damage in patients with diabetic nephropathy.